JP2025503971A5 - - Google Patents
Info
- Publication number
- JP2025503971A5 JP2025503971A5 JP2024544447A JP2024544447A JP2025503971A5 JP 2025503971 A5 JP2025503971 A5 JP 2025503971A5 JP 2024544447 A JP2024544447 A JP 2024544447A JP 2024544447 A JP2024544447 A JP 2024544447A JP 2025503971 A5 JP2025503971 A5 JP 2025503971A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- pharmaceutically acceptable
- mta
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303497P | 2022-01-26 | 2022-01-26 | |
| US63/303,497 | 2022-01-26 | ||
| PCT/US2023/011658 WO2023146989A1 (en) | 2022-01-26 | 2023-01-26 | Compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503971A JP2025503971A (ja) | 2025-02-06 |
| JP2025503971A5 true JP2025503971A5 (enExample) | 2026-02-16 |
Family
ID=85382515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544447A Pending JP2025503971A (ja) | 2022-01-26 | 2023-01-26 | 化合物及び使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250171432A1 (enExample) |
| EP (1) | EP4469447A1 (enExample) |
| JP (1) | JP2025503971A (enExample) |
| WO (1) | WO2023146989A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117658980A (zh) * | 2022-09-08 | 2024-03-08 | 郑州同源康医药有限公司 | 双环类prmt5抑制剂 |
| CN120476118A (zh) * | 2023-01-17 | 2025-08-12 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| CN121241054A (zh) * | 2023-04-14 | 2025-12-30 | 北京双鹤润创科技有限公司 | 氮杂环羰基稠环衍生物及其用途 |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| WO2025217297A1 (en) | 2024-04-09 | 2025-10-16 | Tango Therapeutics, Inc. | Prmt5 inhibitors for use in methods of treating mta-accumulating cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
| WO2022026892A1 (en) * | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| EP4347569A4 (en) * | 2021-06-02 | 2025-03-26 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
-
2023
- 2023-01-26 EP EP23707536.1A patent/EP4469447A1/en active Pending
- 2023-01-26 US US18/833,486 patent/US20250171432A1/en active Pending
- 2023-01-26 JP JP2024544447A patent/JP2025503971A/ja active Pending
- 2023-01-26 WO PCT/US2023/011658 patent/WO2023146989A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025503971A5 (enExample) | ||
| JP7190549B2 (ja) | Ｈｄａｃ阻害剤とｐｄ－１阻害剤との組み合わせ療法 | |
| JP7190548B2 (ja) | Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法 | |
| Li et al. | HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers | |
| Gainor et al. | Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase–positive non–small cell lung cancer relapsing on standard dose alectinib | |
| Singh et al. | Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma | |
| Jimeno et al. | A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer | |
| RU2020114632A (ru) | Терапевтические способы, относящиеся к ингибиторам hsp90 | |
| US20120130144A1 (en) | Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor | |
| JP2019501204A5 (enExample) | ||
| WO2021183318A2 (en) | Methods and compositions relating to improved combination therapies | |
| JP2018508469A5 (enExample) | ||
| JP2019507721A5 (enExample) | ||
| JP2020535173A5 (enExample) | ||
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| JP2020505433A5 (enExample) | ||
| CN105873440A (zh) | 适用于治疗癌症的用于抑制tie2激酶的方法 | |
| WO2020078905A1 (en) | Combination therapy utilizing dna alkylating agents and atr inhibitors | |
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| JP2016530273A (ja) | 癌を治療するためのｈｄａｃ８阻害剤 | |
| JP2025540925A (ja) | 癌の治療におけるアゼノセルチブの断続的投与レジメン | |
| JP2023505222A5 (enExample) | ||
| WO2019222231A1 (en) | Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma | |
| JP2018537519A5 (enExample) | ||
| Chakraborty et al. | AZD4625 is a potent and selective inhibitor of KRASG12C |